We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bacteriophage Protein Shows Antibiotic Potential

By LabMedica International staff writers
Posted on 27 Nov 2013
The T7 bacteriophage produces a protein that blocks Escherichia coli cell division and has the potential of being developed into an antibiotic-replacing drug.

T7 produces over 100 progeny per host cell in less than 25 minutes. More...
If the T7 phage infection completes a successful growth cycle, it invariably culminates in disintegration of the host cell. Bacteriophages take over host cell resources primarily via the activity of proteins expressed early in infection. One such protein produced by the T7 phage is called Gp0.4 (gene product 0.4).

Investigators at Tel Aviv University (Israel) and their colleagues at Duke University (Durham, NC, USA) reported in the November 11, 2013, online edition of the journal, Proceedings of the National Academy of Sciences of the United States of America (PNAS) that Gp0.4 was a direct inhibitor of the E. coli filamenting temperature-sensitive mutant Z division protein.

They showed that a chemically synthesized Gp0.4 bound to purified filamenting temperature-sensitive mutant Z protein and directly inhibited its assembly in vitro. Consequently, expression of Gp0.4 in vivo was lethal to E. coli cultures and resulted in bacteria that were morphologically elongated. Furthermore, the inhibition of cell division by Gp0.4 enhanced the bacteriophage’s competitive ability by enabling them to maximize their progeny number by inhibiting escape of the daughter cells of the infected bacteria.

“Bacteria are infested with bacteriophages, which are their natural enemies and which in most cases destroy them,” said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. “Ever since the discovery of bacteriophages in the early 20th century, scientists have understood that, on the principle of the "enemy of your enemy is your friend"; medical use could be made of phages to fight bacteria.”

“GP0.4 impedes cell division in the E. coli cell. With its capacity for cell division blocked, the bacterium continues to elongate until it dies,” said Dr. Qimron. “Potentially, this protein could be the ideal antibiotic.”

Related Links:

Tel Aviv University
Duke University



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.